GSK has said that a regimen of PD-1 inhibitor Jemperli with PARP inhibitor Zejula has shown efficacy in the second stage of the RUBY trial, which could open up wider use in endometrial cancer. RUBY ...
The European Network for Gynaecological Oncological Trial (ENGOT) groups, the Nordic Society of Gynaecological Oncology – Clinical Trial Unit (NSGO-CTU) and the GOG Foundation, Inc. (GOG-F) are proud ...
GSK plc, a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together, has announced positive headline results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback